Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network

Highlights • The treatment of advanced, refractory thymic epithelial tumors is challenging. • A phase II trial with sunitinib demonstrated its activity in selected patients. • Off-label sunitinib produced an overall response rate of 22% and a PFS of 3.7 months

Bibliographic Details

Published in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-07, Vol.97, p.99-104
Main Authors:	REMON, Jordi, GIRARD, Nicolas, MAZIERES, Julien, DANSIN, Eric, PICHON, Eric, GREILLIER, Laurent, DUBOS, Catherine, LINDSAY, Colin R, BESSE, Benjamin
Format:	Article
Language:	eng
Subjects:	Adolescent Adult Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - pharmacology Clinical Trials, Phase II as Topic Disease-Free Survival Female Hematology, Oncology and Palliative Medicine Humans Indoles - administration & dosage Indoles - pharmacology Male Middle Aged Multicenter Studies as Topic Neoplasm Staging Neoplasms, Glandular and Epithelial - drug therapy Prospective Studies Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins c-kit Pulmonary/Respiratory Pyrroles - administration & dosage Pyrroles - pharmacology Retrospective Studies Second line Sunitinib Thymic carcinoma Thymoma Thymoma - classification Thymoma - drug therapy Thymoma - mortality Thymoma - pathology Thymus Neoplasms - classification Thymus Neoplasms - drug therapy Thymus Neoplasms - mortality Thymus Neoplasms - pathology Treatment Outcome Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!